Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

623
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
623
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

693
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
693
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

1.1K
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
1.1K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.5K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.5K
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

1.4K
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
1.4K
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques01:30

Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques

771
Airway management is essential in emergency and surgical medicine, ensuring ventilation and oxygenation in patients who cannot maintain their own airway. Clinicians use a range of techniques and devices to secure the airway, depending on the patient’s condition and the clinical context. Key methods include endotracheal intubation, rapid sequence intubation (RSI), supraglottic airway devices, and advanced visualization aids. In cases where these approaches fail, surgical airway...
771

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lower plasma resolvin D1 level and greater sputum eosinophilia characterize a cluster of severe asthma patients.

Respiratory research·2026
Same author

Polyunsaturated fatty acids modulation of smoking-related epigenetics and pulmonary outcomes.

Genes & nutrition·2026
Same author

Sustained Reduction in Cardiopulmonary Fitness in Long COVID: A Report from the RECOVER-adult Cohort Study.

JACC. Advances·2026
Same author

The Unusual Suspects.

The New England journal of medicine·2026
Same author

Relevant insights from personalized inhaled carbon monoxide dosing in a safety study in pneumonia and ARDS.

Respiratory research·2026
Same author

Lactate transport inhibition therapeutically reprograms fibroblast metabolism in experimental pulmonary fibrosis.

Science translational medicine·2026

Related Experiment Video

Updated: Mar 21, 2026

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.9K

Recent advances in understanding and treating ARDS.

Rebecca M Baron1, Bruce D Levy1

  • 1Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

F1000Research
|May 10, 2016
PubMed
Summary

Acute respiratory distress syndrome (ARDS) has high mortality and no specific treatments. Recent clinical advances improve outcomes, guiding future ARDS therapies and prevention strategies.

Keywords:
Adjunctive therapyBerlin criteriaLow Tidal Volume VentilationNeuromuscular BlockadeProne Positioning

More Related Videos

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
04:45

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

2.9K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.3K

Related Experiment Videos

Last Updated: Mar 21, 2026

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.9K
Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
04:45

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

2.9K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.3K

Area of Science:

  • Critical Care Medicine
  • Pulmonology
  • Pathophysiology

Background:

  • Acute respiratory distress syndrome (ARDS) is a severe clinical condition characterized by significant morbidity and mortality.
  • Currently, there are no targeted treatment strategies specifically for ARDS.
  • Existing management focuses on supportive care, with outcomes varying widely.

Purpose of the Study:

  • To review recent advances in clinical care for ARDS.
  • To explore the underlying mechanisms of interventions that improve ARDS outcomes.
  • To identify potential future treatment and preventive strategies for ARDS.

Main Methods:

  • Literature review of recent clinical studies and advancements in ARDS management.
  • Analysis of physiological and pathophysiological mechanisms related to ARDS interventions.
  • Synthesis of current evidence to guide future research and clinical practice.

Main Results:

  • Recent clinical care advances have demonstrated improved outcomes in ARDS patients.
  • Understanding intervention mechanisms provides insights into ARDS pathophysiology.
  • Evidence suggests a move towards more targeted supportive and potentially disease-modifying therapies.

Conclusions:

  • Despite challenges, improved clinical care is enhancing ARDS patient outcomes.
  • Further research into intervention mechanisms is crucial for developing novel ARDS treatments.
  • Future strategies may involve a combination of optimized supportive care and targeted therapies.